Naryx Pharma, Inc., a leader in the development of new therapies for patients with chronic sinusitis, said it completed enrolment of a phase IIb trial of Sybryx for the treatment of chronic sinusitis in patients who have undergone previous sinus surgical procedures.

The 180 subject, randomised, double-blind, placebo-controlled Sybryx (tobramycin solution for nasal inhalation) trial will be announced after unblinding the data in the first quarter of 2008.

Previously, the US Food and Drug Administration had granted Fast Track status to Sybryx, acknowledging that chronic sinusitis that persists after sinus surgery has a serious and enduring adverse impact on the day-to-day functioning of patients who suffer from the condition. Moreover, there are no currently approved medical therapies for the treatment of chronic sinusitis, and the results of a previous phase IIa trial demonstrated that Sybryx relieved the symptoms of chronic sinusitis in post-surgical patients.

Robin Campbell, Ph.D., president and CEO, Naryx Pharma, stated, "We are pleased that we have completed this milestone in the development of Sybryx and would like to thank all of the investigators who are participating in the trial. Many patients are suffering from chronic sinusitis, and we look forward to continuing to develop a treatment for this serious and sometimes debilitating disease."

Naryx is a privately-held company dedicated to developing innovative therapies for chronic sinusitis, based on advances in the targeted delivery of medications. Chronic sinusitis is a disease that afflicts up to 35 million people in the US alone. The company will focus on obtaining marketing approvals for its promising intellectual property portfolio of intranasal drug formulations.